Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MLB players and team staff test positive for Covid-19
https://www.cnn.com/2020/06/16/us/mlb-players-coronavirus-report-spt-trnd/index.html
"The second wave has begun," said William Schaffner of the Vanderbilt University School of Medicine.
Even so, he said he "cannot imagine" a second shutdown following the economic, social and cultural impact of the first one.
https://www.cnbc.com/2020/06/15/coronavirus-us-doctor-says-the-second-wave-has-begun.html
FDA pulls emergency authorization for hydroxychloroquine as covid-19 treatment
Food and Drug Administration has withdrawn its emergency use authorization for hydroxychloroquine to treat coronavirus patients. President Trump had repeatedly promoted the antimalarial drug as a way to prevent or treat covid-19.
https://www.washingtonpost.com/nation/2020/06/15/coronavirus-live-updates-us/
FDA WILL CLEAR “GENVIRO.” Nonlinear electrical impedance spectroscopy of viruses using very high electric fields created by nanogap electrodes.
(3) those that are based on the electrical or optical properties of viruses (Cheng et al., 2009). In the first category, PCR-based methods provide high detection sensitivity and accuracy but require long analysis times, costly equipment, and specialized techniques, so their range of use is limited in terms of location and qualified personnel (Yang and Rothman, 2004; Espy et al., 2006; Charlton et al., 2009; Hodneland et al., 2011; Cella et al., 2013). In the second category, immunochromatography can provide a relatively fast, simple, and portable means of virus detection in clinical settings such as hospitals, and has therefore become a mainstream technique; however, it suffers from problems such as low sensitivity and accuracy that impede early-stage detection (Lee et al., 1993, 2009; Patolsky et al., 2004; Reichmuth et al., 2008; Heinze et al., 2009; Wang et al., 2009, 2011; Hassen et al., 2011; Lum et al., 2012; Nguyen et al., 2012). Both categories, moreover, basically involve single-use disposable test units, and can only detect known or specifically targeted viruses. In short, neither category is appropriate in principle for application to continuous virus monitoring of the environment, or detecting new or unspecified viruses. Consequently, neither category holds significant promise for the development of a systematic technology for comprehensive environmental virus monitoring.
“...methods in the third category have two key potential advantages: the ability to continuously monitor the environment, and to detect unspecified viruses and mutants, since biological information on genomes or receptors is not required. A high-sensitivity, accurate virus sensor based on direct measurement of physical properties would enable long-term, continuous virus monitoring, which cannot be achieved by the other two categories. This would represent a groundbreaking advance in virus-monitoring technology.”
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
MUCH WORSE: Mutated coronavirus shows significant boost in infectivity
COVID-19-causing viral variant taking over in the United States and Europe now carries more functional, cell-binding spikes.
June 12, 2020
A new mutation has appeared in the viral variant most common in New York and Italy that makes this spike both more stable and better able to infect cells. (Credit: Andrew Ward lab, Scripps Research).
Viruses with this mutation were much more infectious than those without the mutation in the cell culture system we used,” says Scripps Research virologist Hyeryun Choe, PhD, senior author of the study.
The mutation had the effect of markedly increasing the number of functional spikes on the viral surface, she adds. Those spikes are what allow the virus to bind to and infect cells.
“The number—or density—of functional spikes on the virus is 4 or 5 times greater due to this mutation,” Choe says.
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html
COVID-19 infections will increase very severely and there is no stopping this virus. Infections will skyrocket again, after any reopening. I’m telling you the scientifically certain facts. The only way to reduce infections are with intermittent closures and reopening. Life as we once knew it, will never be the same again for a very long time.
Record spikes in new coronavirus cases, hospitalizations sweep parts of U.S.
Reuters) - New coronavirus cases and hospitalizations in record numbers swept through more U.S. states, including Florida and Texas, as most push ahead with reopening and President Donald Trump plans an indoor rally in Tulsa, Oklahoma.
Alabama reported a record number of new cases for the fourth day in a row on Sunday. Alaska, Arizona, Arkansas, California, Florida, North Carolina, Oklahoma and South Carolina all had record numbers of new cases in the past three days, according to a Reuters tally.
In Louisiana, which had been one of the earlier virus hot spots, new cases were again on the rise with over 1,200 - the most there since May 21.
Nationally, there were over 25,000 new cases reported on Saturday, the highest tally for a Saturday since May 2, in part due to a significant increase in testing over the past six weeks.
https://news.yahoo.com/record-spikes-coronavirus-cases-hospitalizations-144609105.html
Gov. Cuomo threatens ‘reverse’ reopening in Manhattan, Hamptons amid rampant social-distancing violations
https://www.nydailynews.com/coronavirus/ny-coronavirus-reopening-complaints-andrew-cuomo-20200614-3sfxpsocrzfgxdgsj5pcjs3jiy-story.html
Federal government abdicates duty to inform public on coronavirus
CDC officials: 'Pandemic is not over' 03:15
(CNN)No one in a position of authority is regularly talking to the American people about the coronavirus. The national leadership has decided that the best way to inform the public on the daily death toll is to leave the task to private institutions, state and local officials, educators and news anchors.
https://www.cnn.com/2020/06/13/opinions/covid-19-pandemic-federal-government-information-brown/index.html
Yemen, Philippines close missions in Saudi Arabia
Yemeni and Philippine embassies in Riyadh announce emergence of a number of coronavirus cases at diplomatic missions.
Saudi Arabia's numbers continue to climb by more than 3,000 cases daily with more than 123,000 confirmed cases and 930 deaths overall [Amr Nabil/AP Photo] Saudi Arabia's numbers continue to climb by more than 3,000 cases daily with more than 123,000 confirmed cases and 930 deaths overall
https://www.aljazeera.com/news/2020/06/coronavirus-yemen-philippines-close-missions-saudi-arabia-200614090637193.html
Chile health minister resigns amid coronavirus row: Live updates
The health ministry had been accused of tallying deaths using a method that did not reflect the scale of the toll.
Chile President Sebastian Pinera has replaced Health Minister Jaime Manalich amid controversy over the country's figures for deaths from the coronavirus outbreak.
Authorities in Beijing place parts of the city in lockdown after six new domestic coronavirus cases were reported.
India reported its biggest single-day jump in coronavirus infections as the country passed a grim milestone of 300,000 cases.
Brazil became the country with the second-highest coronavirus death toll in the world with 41,828 fatalities, surpassing the death toll of the United Kingdom and second only to the United States.
More than 7.6 million people have now been confirmed to have the coronavirus and at least 426,000 have died, according to data from Johns Hopkins University.
https://www.aljazeera.com/news/2020/06/brazil-coronavirus-toll-world-highest-live-updates-200613002420511.html
At least 44 people have been arrested and charged since March under internet laws for allegedly spreading rumours and propaganda.
The virus has killed many prominent Bangladeshis, including business tycoons, bureaucrats and senior doctors.
On Saturday, Sheikh Abdullah, the state minister for religious affairs and a close ally of the prime minister, died of complications related to COVID-19, the disease caused by the novel coronavirus, after being admitted to a military hospital.
Front-line workers, including police officers, have also been hit by the pandemic.
Two ministers in Prime Minister Sheikh Hasina's cabinet, as well as five members of Parliament, have also been infected, a minister told AFP.
https://www.aljazeera.com/news/2020/06/bangladesh-lecturer-charged-coronavirus-facebook-post-200614115023077.html
Novel coronavirus mutation could spell trouble for vaccine development
“For this study, the team looked at 106 SARS-CoV-2 genome sequences and 39 SARS genome sequences. Their data reveals that this new virus has a much lower mutation rate compared to the original SARS virus. “The observation of this study raised the alarm that SARS-CoV-2 mutation with varied epitope [something an antibody attaches itself to] profile could arise at any time,” the researchers wrote. “[This] means current vaccine development against SARS-CoV-2 is at great risk of becoming futile.”
https://www.news-medical.net/news/20200419/Novel-coronavirus-mutation-could-spell-trouble-for-vaccine-development.aspx
COVID-19 Will Mutate — What That Means for a Vaccine
Early research from scientists at Los Alamos National Laboratory shows that SARS-CoV-2 has mutated into a new form that may be more contagious.
The new strain is responsible for the vast majority of infections reported around the world since mid-March, according to the new study published in the preprint research website BioRxiv Thursday.
In total, the researchers identified 14 strains of COVID-19 and released their findings to help those working on vaccines and treatments.
It’s also unclear whether the new mutation infects and sickens people differently. At this time, the illness and hospitalization rates caused by the new variation seems to be similar.
More data is needed to understand the implications of the new mutations, like whether reinfections after recovery are possible, and whether the changes could affect the vaccines and treatments in development.
https://www.healthline.com/health-news/what-to-know-about-mutation-and-covid-19
“On the frontlines at a NY hospital full of critically ill COVID-19 patients: Part 1/2”
“What Hospitals Fighting The Coronavirus Look Like Around The World”
Doctors keep discovering new ways the coronavirus attacks the body
Damage to the kidneys, heart, brain — even ‘covid toes’ — prompts reassessment of the disease and how to treat it
https://www.washingtonpost.com/health/2020/05/10/coronavirus-attacks-body-symptoms/
Regardless of EUA clearance date speculation, COVID-19 elimination or eradication is utterly impossible, even in the presence of vaccine. COVID-19 Testing will always be necessary. Also remember that influenza mutates and infects every year withstanding new vaccines, annually. Also keep in mind that Polio also infects with various strains that mutate in response to Polio vaccinations - -
http://polioeradication.org/polio-today/polio-prevention/the-virus/vaccine-derived-polio-viruses/
https://www.google.com/search?client=safari&channel=iphone_bm&source=hp&ei=i4zlXuPLIf-EytMPofO5kAk&q=Vaccine+derived+viruses&oq=Vaccine+derived+viruses&gs_lcp=ChFtb2JpbGUtZ3dzLXdpei1ocBADMgIIADIGCAAQFhAeMggIABAWEAoQHjIFCAAQzQIyBQgAEM0CMgUIABDNAjoCCCk6BggpEBYQHjoFCCkQoAE6BQgpELEDOgQIKRANOgYIABAHEB46BAgAEA1QuD5Yx9kBYKHdAWgAcAB4AIABhgGIAfUNkgEEMTguNJgBAKABAqABAbABDw&sclient=mobile-gws-wiz-hp
This phenomenon also occurs with various other viruses, as well.
GOVERNMENT BASED FRAUDS: House coronavirus response coordinator Deborah Birx praised Florida’s official coronavirus dashboard in April as a beacon of transparency. But Jones has asserted that the site undercounts the state’s infection total and overcounts the number of people tested — with the official numbers bolstering the decision to start loosening restrictions on the economy in early May, when the state had not met federal guidelines for reopening. https://www.washingtonpost.com/nation/2020/06/12/rebekah-jones-florida-coronavirus/
2nd COVID-19 Wave? U.S. Still In The 1st One
Just weeks after parts of the U.S. began reopening, coronavirus infections are on the upswing in several states, including Arizona, Utah, Texas and Florida. Dramatic increases in daily case counts have given rise to some unsettling questions: Is the U.S. at the start of a second wave? Have states reopened too soon? And have the recent widespread demonstrations against racial injustice inadvertently added fuel to the fire?
The short, unpleasant answer to the first question is that the U.S. has not even gotten through the current first wave of infections. Since peaking at around 31,000 average new daily cases on April 10, new daily cases dropped to around 22,000 on average by mid-May and have stayed almost steady over the last four weeks. Nationwide more than 800 people continue to die day after day.
https://www.npr.org/sections/health-shots/2020/06/12/876224115/coronavirus-second-wave-nope-were-still-stuck-in-the-first-one
FLORIDA MANIPULATING COVID-19 DATA. In a statement to CBS12 News in West Palm Beach, Fla., Jones said her dismissal came after she refused to "manually change data to drum up support for the plan to reopen."
"As a word of caution," she wrote, "I would not expect the new team to continue the same level of accessibility and transparency that I made central to the process during the first two months. After all, my commitment to both is largely (arguably entirely) the reason I am no longer managing it."
https://www.npr.org/sections/coronavirus-live-updates/2020/05/19/859119865/florida-ousts-top-covid-19-data-scientist
CDC warns U.S. may reimplement strict coronavirus measures if cases go up 'dramatically'
The "pandemic is not over" and it's important to recognize that Covid-19 is still making headlines everywhere, he added.
"Right now, communities are experiencing different levels of transmission occurring, as they gradually ease up onto the community mitigation efforts and gradually reopen," the CDC's deputy director for infectious diseases, Jay Butler, told reporters during a press briefing.
https://www.cnbc.com/2020/06/12/cdc-may-reimplement-strict-coronavirus-rules-if-cases-go-up-dramatically.html
The test results may be the amendment.
FDA AMENDMENTS AND WORLD-WIDE AGREEMENTS:
This Amendment specifically addresses what the company believes are positive changes in the FDA Guidance and/or platforms (EUA updates 4 and 5) initiated on May 4 and May 11, 2020, respectively. The company believes that both of these guidance additions/changes help us as we present our GenViro! Swift :15 Kit and prepare it for commercial sale in anticipation of securing regulatory approval. In addition, the company emphasizes its ongoing support for increased testing as the US is experiencing a substantial uptick in the number of Covid-19 infections in approximately 20 states and the critical need to increase testing worldwide.
Keith Berman CEO of DECN commented, "It is clear from the data and in pronouncements from the vast majority of public-health experts that we need more testing, its accuracy needs to improve, and we need faster results. That's exactly what we are working on with our Covid -19 :15 Swift Kit and why we are filing this 2nd amendment with the FDA."
Leading outlets such as The New York Times have said the current state of testing is not sufficient, calling it "The Wild West". In a late April article the Times also highlighted the fact that "The FDA must stick to its normal process for review but expedite it by giving top priority with its reviewers and bring more on if necessary." Berman continued, "We agree and also believe that this will certainly support smaller, innovative companies with potential game-changing technologies like ours who remain anxious to demonstrate in the market alternative testing solutions."
The company had previously announced that separate Emergency Use Applications (EUA) had been filed and have received Pre-EUA Acknowledgement letters from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Swift Kit for professional use in commercial and group settings and device (serial number) PEUA200947, GenViro Covid-19 Screening Kit for at-home use.
Decision Diagnostics through its Pharma Tech Solutions, Inc. subsidiary is an 18-year old diabetes testing products firm, high-level manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for its own proprietary regulated medical devices. Subject to FDA authorization of its GenViro! Swift kits, DECN anticipates adopting its further developed impedance technology, first utilized for its diabetic testing products, to implement the manufacturing and distribution of its GenViro! Covid-19 :15 Swift test kits in the U.S., Canada, and worldwide.
Bioimpedance Devices for Detection of Lymphedema
APPROVED BY GOVERNING BODIES:
(EIS - - ELECTROCHEMICAL IMPEDANCE) Devices that have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process to aid in the assessment of lymphedema are summarized below:
https://al-policies.exploremyplan.com/portal/web/al-policies/member-policies/-/asset_publisher/4EaSGmJSQJLN/content/mp-438/78515
FDA Approves EIS System Nevisense 3.0 for the Early Detection of Melanoma
May 01, 2020
FDA granted approval to an electrical impedance spectroscopy system (EIS), Nevisense 3.0, the third-generation of the SciBase Nevisense system, for the early detection of melanoma, SciBase announced in a press release.
https://www.targetedonc.com/view/fda-approves-eis-sytem-nevisense-3-0-for-the-early-detection-of-melanoma
Bioimpedance based medical devices
Bioimpedance is a well-known method for detecting and monitoring different biological processes. The medical industry is using bioimpedance but not nearly enough. The problem is in the complex nature of impedance measurement. However, for companies interested in developing a diagnostic medical device, it is definitely worth looking into. Eliko can help as we have developed impedance-based measurement devices for well over a decade already – take a look at our latest smart needle project.
https://www.eliko.ee/bioimpedance-medical-devices/
THIS IS THE EXACT STAGE OF DEVELOPMENT DECN IS IN RIGHT NOW:
“Once established, method parameters including circuit model are fixed (Orazem and Tribollet 2007), and frequency ranges used for EIS measurements can be shortened a minimum requirement (Niloy et al. 2017; Ramaswamy et al. 2013; Tsai and Wang 2016; Grassini et al. 2015).
Once established, method parameters including circuit model are fixed (Orazem and Tribollet 2007), and frequency ranges used for EIS measurements can be shortened a minimum requirement (Niloy et al. 2017; Ramaswamy et al. 2013; Tsai and Wang 2016; Grassini et al. 2015). For example, a change of resistance in contaminated milk could be detected by measuring with only one frequency, while resistance remained the same over the rest of the tested frequency range (Durante et al. 2016). Once the frequencies of interest have been established, additional frequency measurements serve only to extend the analysis time while providing no additional relevant information (Seoane et al. 2012).”
https://link.springer.com/article/10.1007/s10544-019-0406-9
While electrochemical impedance sensing is widely used in tissue analysis such as body composition measurement, its use in point-of-care patient testing is yet to be widely adopted.
Impedance sensing is already employed in clinical diagnosis such as in electrical impedance myography (Sanchez and Rutkove 2017), blood impedance analysis (Ghafar-Zadeh et al. 2010) and electrical impedance tomography (Adler and Boyle 2017).
These bioimpedance methods apply electrical signals directly to patient tissue, or to patient samples in a laboratory, both of which require specialized medical equipment and training (Shaw 2016).
EIS relies on the physical and chemical properties of molecules to alter the transmission of electrical current (Carminati and Li 2017).
EIS can be performed using a variety of bench-top hardware, including electrochemical suites with a frequency response analyzer (FRA), dedicated impedance analyzers or basic inductance-capacitance-resistance meters.
An amplitude reduction in the response signal is expected, due to energy lost by the signal when passing through the sample under test and relates inversely to the impedance magnitude (|Z|) (Fig. 1b).
System generated response data including calculated model components and magnitude values were exported from Nova for statistical analysis. Impedance magnitude (Fig. 4a) showed high precision between repeats on the same load, with CV values for repeats ranging from 0.099% to 0.00729% of the mean. Despite this, fitting the impedance data to the equivalent circuit model (Fig. 4b) did not approximate the resistor values in the test loads. The Rct values calculated for test loads were not significantly different, and coefficients of variation ranged from 72.3% of the mean (1200 O load) to 169.8% of the mean (1560 O load). Each test load could be distinguished from Nova calculated magnitude values with very high precision, without requirement for model fitting. Impedance magnitudes were also similar between frequencies for each solid-state test load, but Nova analysis software did not provide a tool to simultaneously compare with a standard value to determine diagnostic significance. When fitting analysis was applied to match the load to its real-world model, none of the load resistors could be identified by Nova software with accuracy or reliability, even in the absence of electrochemical variables.
THIS IS THE EXACT STAGE OF DEVELOPMENT DECN IS IN RIGHT NOW:
Once established, method parameters including circuit model are fixed (Orazem and Tribollet 2007), and frequency ranges used for EIS measurements can be shortened a minimum requirement (Niloy et al. 2017; Ramaswamy et al. 2013; Tsai and Wang 2016; Grassini et al. 2015).
Once established, method parameters including circuit model are fixed (Orazem and Tribollet 2007), and frequency ranges used for EIS measurements can be shortened a minimum requirement (Niloy et al. 2017; Ramaswamy et al. 2013; Tsai and Wang 2016; Grassini et al. 2015). For example, a change of resistance in contaminated milk could be detected by measuring with only one frequency, while resistance remained the same over the rest of the tested frequency range (Durante et al. 2016). Once the frequencies of interest have been established, additional frequency measurements serve only to extend the analysis time while providing no additional relevant information (Seoane et al. 2012).
https://link.springer.com/article/10.1007/s10544-019-0406-9
“In the past, when people would ask Fauci to describe a potential disease that he feared most, he said he would often describe it as something that was a brand new respiratory infection that likely jumped from an animal and had a very high degree of transmissibility.
The world has seen outbreaks that have at least some of those characteristics, he said, but Covid-19 had all of those characteristics combined.
"Now we have something that turned out to be my worst nightmare," Fauci said. "In the period of four months, it has devastated the world."
The pandemic has killed more than 111,700 people in the United States, and nearly 409,000 worldwide, according to Johns Hopkins University. Around the globe there have been more than 7 million people infected.
It was "unexpected how rapidly," it would spread, he said.
"It just took over the planet," Fauci added, "And it isn't over yet."
Fauci also said there is still a lot to learn about the long-term negative effects of Covid-19 infection on patients.
"The thing that we don't yet fully appreciate is what happens when you get infected and you get serious disease and you recover? What are the long-term durable negative effects of that infection?" Fauci said.
Fauci explained that because there's still not enough experience with the virus, scientists don't know what patients who have recovered will be like in six months.
"We don't know the extent of full recovery or partial recovery, so there's a lot we need to learn," he said.“
https://www.cnn.com/2020/06/09/health/fauci-coronavirus-worst-nightmare/index.html
Longs: Hold your shares. FDA clearance is very close. Mr. BERMAN is under a lot of pressure and The Bio is too. We should be receiving news on the tests, and soon after that, FDA’s clearance. Do not sell your shares when we are cleared. There will be a few rallies, because long holders will want to sell. The clearance will guarantee active trading and bring in more volume. This pattern will continue and the volume will increase with big block positions. GET READY! GREAT NEWS ON THE WAY. I understand what’s happening, clearly.
THANKS ANGEL. I’M PLEASED FHAT YOU UNDERSTAND THIS. BUT EVEN AFTER AN EUA, BERMAN WILL NOT DISCLOSE THE COMPANY’S INTELLECTUAL INTERESTS OR INTELLECTUAL PROPERTY. I KNOW THEY HAVE IT AND BY THE TEST RESULTS, IT DEFINITELY WORKS. THE PICTURES AND RESULTS WERE IN ACCORD. THIS IS GONNA BE GREAT.
1). “EUA allows FDA to authorize use of an unapproved MCM, in anticipation of a potential emergency or during an actual emergency involving a chemical, biological, radiological, or nuclear agent, or emerging infectious disease, if certain criteria are met.”
2). “FDA works with medical countermeasure developers to prepare Pre-EUA packages, when appropriate. A Pre-EUA package contains data and information about the safety, quality, and efficacy of the product, its intended use...”
3). “The pre-EUA process allows FDA scientific and technical subject matter experts to begin a review of information and assist in the development of conditions of authorization, fact sheets, and other documentation that would be needed...”
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/how-submit-pre-eua-vitro-diagnostics-fda
They don’t need the working prototype to claim it works, so long as the development is progressing with the parameters determined through the testing phase - - pay very close attention - - that was determined to work on the H5N1 Virus. Be very open minded here, now. If the initial test did detect the H5N1 Virus, and functioned as specified, then the configuration could be modified and adjusted to detect COVID-19, because it can be modified with the correct configuration, as for H5N1. I am not saying they are the same configurations. I am saying that the configurations can be modified. As long as you can determine that the configuration can be made for the intended purpose, without the finished product, the plans to produce it would suffice, as this is the “Development phase,” that the PRE-EUA also allows, prior to complete submission. Believe me when I say they have it and it works. THOUGH BERMAN CAN GET AHAEAD OF HIMSELF, EXCITED AND ALL, He is also very smart to keep the ends open for interpretation because his plans point to the device in development to produce the unit with the correct configuration implemented to measure the impedance for COVID-19. If you think it’s easy to determine the impedance limits through trial, error and elimination, then you do not understand the scientific process of perfecting the device. You must understand that the point where impedance begins is the difference of the entire applied current and the point where impedance ends is the fingerprint, specific to COVID-19. How much of the current is resisted must be measured and configured from max-capacitance, to start of impedance to end of impedance. Then you can determine the exact current based on those parameters and build the device. This is where they are, right now. And they are going to complete it, because the process of elimination dictates those parameters.
If DECN lacked value then why do attackers find it greater value to continue their oppressive attacks on the company? DECN is offering a tremendous technological revolution that continues to stand amidst the attacks. There is a reason that DECN can withstand the onslaught, that only invites new attackers to no adverse effect, but only validating the GENVIRO’s perceived purpose.
The test results were posted, though unnecessary, and they were in the ranges of 97%-99% by visual inspection of the hematocrit ranges. The other tests that you cite have no relevancy to GENVIRO. AND ADDITIONAL test data will be provided to demonstrate the accuracy with virus samples. Your predictions and assumptions are exactly what they are, and nothing more.
DECN IS NOW A DISRUPTIVE TECHNOLOGY COMPANY. THIS IS WHY WE ARE PATIENTLY WAITING FOR THE IMMINENT ROCKET RIDE. HERE’S WHY: DECN’S ELECTROCHEMICAL IMPEDANCE PRESENTS A PARADIGM SHIFT IN DIAGNOSTICS. THIS IS NOT JUST ABOUT COVID-19, BUT ALL VIRUSES AND EVEN OTHER DISEASES. MOST DIAGNOSTICS USE MOLECULAR PCR VIRUS DIAGNOSTICS. VERY FEW USE ELECTROCHEMICAL IMPEDANCE. DECN IS PRESENTING A POTENTIAL DISRUPTION IN THE ACCEPTED AND IMPLEMENTED DIAGNOSTIC TECHNIQUES AND ALSO VERY LESS EXPENSIVE. FOR BIG PHARMA DECN IS PRESENTING A THREAT TO THEIR BUSINESS AND PROFITS AND PIPELINES. THIS IS THE PRIMARY REASON WHY DECN IS UNDER A MALICIOUS ATTACK.
NOW, AS DECN INVESTORS YOU SHOULD BE PROUD, HAPPY AND EXCITED TO BE PART OF THIS PROCESS IN THE MAKING AND INTRODUCTION OF A BENEFICIAL AND PIONEERING TECHNOLOGY AND COMPANY. WITHOUT DOUBT THIS IS PLAYING OUT LIKE A WAR BETWEEN THE OVER DOGS BEATING ON THE UNDERDOG. BUT IT BECOMES FAIRLY OBVIOUS THAT THE OVER DOGS ARE ONLY ACTING OUT OF FEAR. AND THEY ARE WORRIED BECAUSE THEY DON’T WANT TO LOSE ANYTHING TO THE VALUABLE DECN IMPEDANCE TECHNOLOGY THAT CONFRONTS THEM.
IN OTHER WORDS, THE ATTACKS ON DECN ONLY SUBSTANTIATE THE VALUE OF THE COMPANY’S TECHNOLOGY. SO IF YOU ARE LONG AND STRONG THE ROCKET RIDE WILL BE WORTH THE TICKETS.
Cerebrotech's Visor Device Receives FDA Clearance
According to the company, Visor is a noninvasive bioimpedance spectroscopy device that detects changes and distribution of cerebral fluids using Cerebrotech's Volumetric Impedance Phase-shift Spectroscopy (VIPS) technology.
https://evtoday.com/news/cerebrotechs-visor-device-receives-fda-clearance
How to Submit a Pre-EUA for In vitro Diagnostics to FDA
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/how-submit-pre-eua-vitro-diagnostics-fda
“Pre-EUA Acknowledgement letter from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Screening Kit. This grant by the FDA is a major milestone in our GenViro!™ Covid-19 test kit development...”
https://finance.yahoo.com/news/decn-receives-pre-eua-acknowledgement-141500818.html
GREAT STUFF:$$$$$$$$
AT FDA: WE ONLY HAVE: “PHARMA TECH SOLUTIONS” and See: “THE BIO,” BELOW.
Initial Distributor/Importer: Yes
*Note Firm May Have Additional “Establishment Types.
Please Review Listings For Further Information.”
Operator Number: 10027212
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?rid=94109
THE BIO CO., LTD Owner/Operator Number: 10051261
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?rid=191768
DECISION DIAGNOSTICS IS NOT AT THE FDA, BUT ONLY AS AN “AGENT or OFFICIAL CORRESPONDENT.” THIS MEANS THAT THE DEVICES ARE ONLY UNDER “THE BIO” and/or “PHARMA TECH SOLUTIONS.” AND THIS IS WHY THE GENVIRO IS BEING DISTRIBUTED OR SOLD UNDER PHARMA TECH SOLUTIONS. BUT “THE BIO” OWNS THE WHOLE OPERATION THROUGH THE KOREAN ANGEL INVESTORS AND FUNDS.
https://fda.report/Company/Pharma-Tech-Solutions-Inc
http://www.pharmatechsolutions.co/genviro.html